ALS LIMITED — Capital/Financing Update 2022

Feb 28, 2022

==> picture [180 x 69] intentionally omitted <==

asx/media release

1 March 2022

ALS upgrades FY22 underlying NPAT guidance range to $260 million to $265 million

ALS (ASX: ALQ) announces that it has upgraded FY22 underlying net profit after tax (NPAT) guidance to between $260 million and $265 million. The midpoint represents a 6.3% increase compared to the midpoint of the prior range provided at the H1 FY22 results announcement.

The upgrade is driven by several factors. Geochemistry is experiencing strong sample volume growth and price improvement as it benefits from the capacity increase being delivered during FY22, combined with the additional capacity provided by the acquisition of MinAnalytical in December 2021. Life Sciences volumes remain above pre-pandemic levels with all businesses and key geographies performing well. In addition, foreign exchange is making a positive contribution to the second half of FY22 compared to the prior corresponding period.

While there is some pressure on input costs across the Group, this is being managed by price increases and improved procurement practices, although the inflationary environment remains volatile.

The FY22 results will be announced on Wednesday 25 May 2022.

Approved for release by ALS Limited Board.

-ENDS-

For further information please contact:

Raj Naran Simon Starr Managing Director and CEO Head of Investor Relations ALS Limited ALS Limited +61 7 3367 7900 +61 428 275 170 simon.starr@alsglobal.com

About ALS Limited

ALS is a global Testing, Inspection & Certification business. The company’s strategy is to broaden its exposure into new sectors and geographies where it can take a leadership position.